News | October 17, 2007

XTent to Present CUSTOM I, II Trial Data at TCT 2007

October 18, 2007 – XTENT Inc. announced that two-year data from the CUSTOM I trial and 1-year data from the CUSTOM II trial of the company’s investigational Custom NX drug-eluting stent (DES) system will be presented at the Cardiovascular Research Foundation’s (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., which is taking place October 20 to 25.

In addition, the company will conduct a number of activities during the meeting including an analyst webcast and teleconference to review the CUSTOM I and CUSTOM II clinical data, an evening drug-eluting stent symposium, and an exhibition at booth 6097 on Level 2 of the Washington Convention Center.

Schedule of Events

Sunday, October 21
Event: The Drug-Eluting Stent Summit: The XTENT CUSTOM Biolimus-Eluting Modular Stent Program (Focus on Multivessel and Diffuse Disease)

Pieter Stella, M.D., director of Cardiology, University Medical Center, Utrecht, Netherlands, will present an historical overview and current perspective on the treatment of multivessel coronary disease and the treatment of long lesions. An overview of the Custom NX DES System with respect to the treatment of multivessel and diffuse disease will be discussed, along with the one-year follow-up results of the CUSTOM II Trial.

Time/Location: 3:16-3:26 p.m. EDT; Ballroom C, 3rd Floor, Washington Convention Center
Event: Evening Symposium – Delivering Safety to Today’s Patients

Professor Eberhard Grube, M.D., chief of Cardiology at the HELIOS Heart Center in Siebgurg, Germany and principal investigator of the CUSTOM I and II clinical trials, will review the results to date from Biolimus A9 DES clinical trials and registries. Professor Grube will present two-year results from the CUSTOM I clinical trial and one-year results from the CUSTOM II clinical trial.

Bernard de Bruyne, M.D., Ph.D, Cardiovascular Center, OLV Hospital in Aalst, Belgium, will provide an overview of the Custom NX technology in a presentation titled "XTENT Custom NX DES Systems: A Novel Approach to the Percutaneous Treatment of Coronary Artery Disease (CAD)."

Time/Location: 8:00-10:00 p.m. EDT; Renaissance Washington, D.C. Hotel, Grand Ballroom, 999 Ninth Street NW

Monday, October 22
Event: Analyst Webcast and Teleconference on CUSTOM I and CUSTOM II Data

For more information: www.xtentinc.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init